Ignite Creation Date:
2024-05-06 @ 6:28 PM
Last Modification Date:
2024-10-26 @ 2:48 PM
Study NCT ID:
NCT05673928
Status:
RECRUITING
Last Update Posted:
2024-02-29
First Post:
2022-12-30
Brief Title:
A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine T-DM1 in Patients with HER2-positive Metastatic Solid Tumors and Metastases to Brain TUCATEMEB
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-05-16
Start Date Type:
ACTUAL
Primary Completion Date:
2027-03-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-03-01
Completion Date Type:
ESTIMATED
First Submit Date:
2022-12-30
First Submit QC Date:
December 30 2022
Study First Post Date:
2023-01-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-09-13
Last Update Post Date:
2024-02-29
Last Update Post Date Type:
ACTUAL